Non Animal Testing, Alternative Test Methods, In Vitro Toxicology, IIVS | FDA Releases New Guidance Recommending Alternatives to LLNA
post-template-default,single,single-post,postid-560877,single-format-standard,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-17.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive

FDA Releases New Guidance Recommending Alternatives to LLNA

April 22, 2020

FDA releases new guidance recommending the performance of alternative test methodologies in lieu of the murine-based Local Lymph Node Assay (LLNA) to assess skin sensitization potential for topically-applied drug products. This information can be found at, pages 7-8.

IIVS offers multiple assays and provides guidance to companies and organizations interested in using non-animal approaches to evaluate this endpoint. Learn more about our skin sensitization testing capabilities at or contact us at